HT
ABCL icon

Headlands Technologies’s AbCellera Biologics ABCL Stock Holding History

Headlands Technologies’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$637K Sell
182,656
-6,131
-3% -$22.1K 0.07% 305
2025
Q4 		$646K Buy
188,787
+69,196
+58% +$309K 0.05% 356
2025
Q3 		$602K Buy
119,591
+81,796
+216% +$360K 0.05% 321
2025
Q2 		$130K Buy
+37,795
New +$94.1K 0.02% 573
2024
Q3 		– Sell
-49,393
Closed -$146K – 1145
2024
Q2 		$146K Buy
+49,393
New +$187K 0.02% 543

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Headlands Technologies's ABCL Position: Q1 2026 in Review

Headlands Technologies reduced its AbCellera Biologics (ABCL) stake by 3.2% in Q1 2026, selling an estimated $22.1K and leaving 182,656 shares worth $637K. The position accounts for 0.07% of the portfolio, ranked #305.

Headlands Technologies first reported a position in ABCL in Q2 2024 and has held it in 5 quarters since. The position peaked at $646K in Q4 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Headlands Technologies held 182,656 shares of AbCellera Biologics worth $637K as of Q1 2026.
  • Headlands Technologies sold 6,131 AbCellera Biologics shares in Q1 2026, an estimated $22.1K.
  • AbCellera Biologics made up 0.07% of Headlands Technologies's portfolio in Q1 2026, its #305 holding.
  • Headlands Technologies first reported a position in AbCellera Biologics in Q2 2024 and has held it in 5 quarters since.
  • Headlands Technologies's AbCellera Biologics position peaked at $646K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.